Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-10-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Retrospective Evaluation of Quality of life data collected on men who underwent iodine seed brachytherapy at the University Hospital Zurich

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms, Prostate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention in this retrospective study

No Intervention in this retrospective Analysis.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male \> 18 years of age
* iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich

Exclusion Criteria

* No iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich

Minimum Eligible Age

48 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Daniel Rudolf Zwahlen

MD, MBA

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel R Zwahlen, MD, MBA

Role: PRINCIPAL_INVESTIGATOR

Kantonsspital Graubuenden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kantonsspital Graubuenden, Department of Radiaton Oncology

Chur, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KEK-ZH-Nr. 2015-0573

Identifier Type: -

Identifier Source: org_study_id